Antipsychotic drug treatment of schizophrenia in later life: Results from the European cross-sectional AMSP study

References

• Abel KM, Drake R, Goldstein JM. 2010. Sex differences in schizophrenia. Int Rev Psychiatry. 22(5):417–428.
   PubMed Web of Science ®Google Scholar
• Albitar O, Harun SN, Zainal H, Ibrahim B, Sheikh Ghadzi SM. 2020. Population pharmacokinetics of clozapine: a systematic review. Biomed Res Int. 2020:9872936.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Streim J, Carpenter D, Docherty JP. 2004. Using antipsychotic agents in older patients. J Clin Psychiatry. 65(Suppl 2):5–99. discussion 100-102; quiz 103-104.
   PubMed Web of Science ®Google Scholar
• Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, Gregory CJ, Haddad PM, Howes OD, Jones I, et al. 2020. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 34(1):3–78.
   PubMed Web of Science ®Google Scholar
• Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. 2008. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 48(2):157–165.
   PubMed Web of Science ®Google Scholar
• By the American Geriatrics Society Beers Criteria Update Expert P. 2019. American Geriatrics Society 2019 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 67(4):674–694.
   PubMed Web of Science ®Google Scholar
• Castberg I, Westin AA, Skogvoll E, Spigset O. 2017. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 136(5):455–464.
   PubMed Web of Science ®Google Scholar
• Cohen CI, Meesters PD, Zhao J. 2015. New perspectives on schizophrenia in later life: implications for treatment, policy, and research. Lancet Psychiatry. 2(4):340–350.
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R. 2001. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 158(5):765–774.
   PubMed Web of Science ®Google Scholar
• Danivas V, Venkatasubramanian G. 2013. Current perspectives on chlorpromazine equivalents: Comparing apples and oranges!. Indian J Psychiatry. 55(2):207–208.
   PubMed Web of Science ®Google Scholar
• Deutsche Gesellschaft für Psychiatrie und Psychotherapie PuNeV. 2019. S3-Leitlinie Schizophrenie. [accessed 2021 Mar 30]. https://www.awmf.org/uploads/tx_szleitlinien/038-009l_S3_Schizophrenie_2019-03.pdf.
   Google Scholar
• Erickson MA, Banks WA. 2019. Age-associated changes in the immune system and blood(-)brain barrier functions. Int J Mol Sci. 20(7):1632.
   Web of Science ®Google Scholar
• European Medicines Agency. 2011. EMA geriatric medicines strategy (EMA/CHMP/137793/2011). EMEA; [accessed 2021 Jan 28]. https://www.ema.europa.eu/en/documents/other/geriatric-medicines-strategy_en.pdf.
   Google Scholar
• Expert Working Group of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 1994. Guideline for industry, studies in support of special populations: geriatrics. [accessed 2021 Oct 19] https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-special-populations-geriatrics-step-5_en.pdf.
   Google Scholar
• Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. 2016. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust NZ J Psychiatry. 50(5):410–472.
   PubMed Web of Science ®Google Scholar
• Greil W, Haberle A, Schuhmann T, Grohmann R, Baumann P. 2013. Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. Swiss Med Wkly. 143:w13772.
   PubMed Web of Science ®Google Scholar
• Grohmann R, Engel RR, Ruther E, Hippius H. 2004. The AMSP drug safety program: methods and global results. Pharmacopsychiatry. 37(Suppl 1):S4–S11.
   PubMedGoogle Scholar
• Grover S, Chakrabarti S, Kulhara P, Avasthi A. 2017. Clinical Practice Guidelines for Management of Schizophrenia. Indian J Psychiatry. 59(Suppl 1):S19–S33.
   PubMedGoogle Scholar
• Guideline Writing Group. 2021. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. Washington, DC: American Psychiatric Association.
   Google Scholar
• Holt S, Schmiedl S, Thurmann PA. 2010. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 107(31–32):543–551.
   PubMed Web of Science ®Google Scholar
• Howard R, Rabins PV, Seeman MV, Jeste DV. 2000. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry. 157(2):172–178.
   PubMed Web of Science ®Google Scholar
• Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. 2009. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse. 63(4):282–290.
   PubMed Web of Science ®Google Scholar
• Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N. 1993. Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull. 19(4):817–830.
   PubMed Web of Science ®Google Scholar
• Jeste DV, Wolkowitz OM, Palmer BW. 2011. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr Bull. 37(3):451–455.
   PubMed Web of Science ®Google Scholar
• Leucht S, Samara M, Heres S, Davis JM. 2016. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 42 Suppl 1(Suppl 1):S90–S94.
   PubMedGoogle Scholar
• Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, et al. 2017. Dementia prevention, intervention, and care. Lancet. 390(10113):2673–2734.
   PubMed Web of Science ®Google Scholar
• Mamo DC, Sweet RA, Chengappa KN, Reddy RR, Jeste DV. 2002. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Int J Geriatr Psychiatry. 17(11):1012–1017.
   PubMed Web of Science ®Google Scholar
• Marriott RG, Neil W, Waddingham S. 2006. Antipsychotic medication for elderly people with schizophrenia. Cochrane Database Syst Rev. 2006:CD005580.
   Google Scholar
• National Institute for Health and Care Excellence (NICE) 2014. Psychosis and schizophrenia in adults: prevention and management. [accessed 30 Mar 2021]. www.nice.org.uk/guidance/cg178.
   Google Scholar
• Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. 2017. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry. 62(9):604–616.
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Turrina C, Valsecchi P. 2010. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf. 33(4):273–288.
   PubMed Web of Science ®Google Scholar
• Schneider M, Pauwels P, Toto S, Bleich S, Grohmann R, Heinze M, Greiner T. 2020. Severe weight gain as an adverse drug reaction of psychotropics: Data from the AMSP project between 2001 and 2016. Eur Neuropsychopharmacol. 36:60–71.
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network. 2013. SIGN 131 • Management of schizophrenia [accessed 30 Mar 2021]. https://www.sign.ac.uk/assets/sign131.pdf.
   Google Scholar
• Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC. 2011. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging. 28(12):961–980.
   PubMed Web of Science ®Google Scholar
• Tampi RR, Young J, Hoq R, Resnick K, Tampi DJ. 2019. Psychotic disorders in late life: a narrative review. Ther Adv Psychopharmacol. 9:2045125319882798.
   Web of Science ®Google Scholar
• Toto S, Grohmann R, Bleich S, Frieling H, Maier HB, Greil W, Cordes J, Schmidt-Kraepelin C, Kasper S, Stubner S, et al. 2019. Psychopharmacological treatment of schizophrenia over time in 30 908 inpatients: data from the AMSP study. Int J Neuropsychopharmacol. 22(9):560–573.
   PubMed Web of Science ®Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Jr., Tollefson GD. 1997. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 17(5):407–418.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services - Food and Drug Administration. 2020. Geriatric information in human prescription drug and biological product labeling, guidance for industry. [accessed 15 Apr 2021]. https://www.fda.gov/media/142162/download.
   Google Scholar
• U.S. Food and Drug Administration – Center for Drug Evaluation and Research. 2005. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. [accessed 15 Apr 2005]. www.fda.gov/cder/drug/advisory/antipsychotics.htm.
   Google Scholar
• Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. 2009. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry. 70(3):397–405.
   PubMed Web of Science ®Google Scholar
• Uchida H, Mamo DC. 2009. Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry. 33(6):917–920.
   PubMed Web of Science ®Google Scholar
• Uchida H, Pollock BG, Bies RR, Mamo DC. 2009. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther. 86(4):360–362.
   PubMed Web of Science ®Google Scholar
• Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tanabe A, Inagaki A, Watanabe K, Yagi G, Tomita M. 2008. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry. 16(7):584–593.
   PubMed Web of Science ®Google Scholar
• Verheggen ICM, de Jong JJA, van Boxtel MPJ, Gronenschild E, Palm WM, Postma AA, Jansen JFA, Verhey FRJ, Backes WH. 2020. Increase in blood-brain barrier leakage in healthy, older adults. Geroscience. 42(4):1183–1193.
   PubMed Web of Science ®Google Scholar
• Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. 2005. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 353(22):2335–2341.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chan GL, Holden JE, Dobko T, Mak E, Schulzer M, Huser JM, Snow BJ, Ruth TJ, Calne DB, et al. 1998. Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse. 30(1):56–61.
   PubMed Web of Science ®Google Scholar
• Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. 2010. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc. 58(9):1749–1757.
   PubMed Web of Science ®Google Scholar